Strategic Alliances

Our business strategy is to do what we do best-to discover unique antisense drugs and develop these drugs to key value inflection points. We discover new drugs, outlicense our drugs to partners and build a broad base of license fees, milestone payments and royalty income. We maximize the value of the drugs we discover by putting them in the hands of quality partners with late-stage development and commercialization expertise.

Additionally, we created a consortium of smaller companies that can broadly exploit the technology with their expertise in specific disease areas. We call these smaller companies our satellite companies. Beyond human therapeutics, we benefit from the commercialization of products of our inventions by other companies that are better positioned to maximize the commercial potential of these inventions, such as our Ibis Biosciences satellite company, which we recently sold to Abbott Molecular Inc.

Since 2007, our partnerships have generated an aggregate of more than $750 million in payments from licensing fees, equity purchase payments and milestone payments. In addition, for our partnered drugs we have the potential to earn approximately $2.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements.

Pharmaceutical Partners

Companies that help develop, market, and distribute antisense drugs.

Learn More

Satellite Companies

Companies that enable us to advance RNA-based therapeutic opportunities.

Learn More